CTLA4 and neoplasm: Plasmids were designed to express an optimized anti-CTLA-4 mAb (p(aCTLA-4)) or anti-PD-1 mAb (p(aPD-1)), and were evaluated in a subcutaneous MC38 mouse tumor model.